Mesalamine and Jakafi drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Mesalamine (mesalamine) and Jakafi (ruxolitinib phosphate). Common drug interactions include ill-defined disorder among females and anaemia among males.

The phase IV clinical study analyzes what interactions people have when they take Mesalamine and Jakafi. It is created by eHealthMe based on reports of 30 people who take the same drugs from the FDA, and is updated regularly.

What is Mesalamine?

Mesalamine has active ingredients of mesalamine. It is often used in ulcerative colitis. eHealthMe is studying from 28,053 Mesalamine users. Check the latest studies of Mesalamine.

What is Jakafi?

Jakafi has active ingredients of ruxolitinib phosphate. It is often used in primary myelofibrosis. eHealthMe is studying from 56,530 Jakafi users. Check the latest studies of Jakafi.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

30 people who take Mesalamine and Jakafi together, and have interactions are studied.

Mesalamine and Jakafi drug interactions.

What are the common drug interactions of Mesalamine and Jakafi, by gender? *:

female:

Ill-defined disorder
Palpitations (feelings or sensations that your heart is pounding or racing)
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
White blood cell count decreased
Rash erythematous (redness of the skin)
Therapeutic response unexpected

male:

Anaemia (lack of blood)
Fall
Haemoglobin decreased
Oedema peripheral (superficial swelling)
Peripheral swelling
Platelet count decreased
Skin injury
Abdominal distension
Aphthous stomatitis (mouth ulcer)
Dyspnoea (difficult or laboured respiration)

What are the common drug interactions of Mesalamine and Jakafi, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Abdominal distension
Anaemia (lack of blood)
Aphthous stomatitis (mouth ulcer)
Dyspnoea (difficult or laboured respiration)
Early satiety (feeling full before completing a normal sized meal)
Fall
Fatigue (feeling of tiredness)
Gastroenteritis viral (inflammation of stomach and intestine caused by virus infection)
Hand fracture
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)

40-49:

n/a

50-59:

n/a

60+:

Ill-defined disorder
Palpitations (feelings or sensations that your heart is pounding or racing)
Fatigue (feeling of tiredness)
Gastrointestinal angiodysplasia haemorrhagic (a small vascular malformation of the gut with bleeding)
Oedema peripheral (superficial swelling)
Peripheral swelling
Skin injury
Weight decreased
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
White blood cell count decreased

What are the existing conditions these people have? *

Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 9 people, 30.00%

* Approximation only. Some reports may have incomplete information.

Do you take Mesalamine and Jakafi?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously